In 1952 researchers at Ciba discovered the first orally available vasodilator, hydralazine. A major shortcoming of hydralazine monotherapy was that it lost its effectiveness over time (tachyphylaxis). In the mid-1950s Karl H. Beyer, James M. Sprague, John E. Baer, and Frederick C. Novello of Merck and Co. discovered and developed chlorothiazide, which remains the most widely used antihypertensive drug today. This development was associated with a substantial decline in the mortality rate among people with hypertension. The inventors were recognized by a Public Health Lasker Award in 1975 for "the saving of untold thousands of lives and the alleviation of the suffering of millions of victims of hypertension". COUNT 10
QSN1 Who discovered Hydralazine? ANS1 researchers at Ciba QSN2 Why were the researchers recognized in 1975? ANS2 the saving of untold thousands of lives and the alleviation of the suffering of millions of victims of hypertension QSN3 Who developed Chlorothiazide? ANS3 Karl H. Beyer, James M. Sprague, John E. Baer, and Frederick C. Novello of Merck and Co QSN4 What is  Chlorothiazide used to treat? ANS4 hypertension QSN5 What was the main shortcoming in the drug Hydralazine? ANS5 lost its effectiveness over time QSN6 What was the name of the first oral vasodilator? ANS6 hydralazine QSN7 What is the most used antihypertensive drug today? ANS7 chlorothiazide QSN8 Beyer, Sprague, Baer, and Novello received what award in 1975? ANS8 Public Health Lasker Award QSN9 In what year was hydralazine discovered? ANS9 1952 QSN10 Chlorothiazide helped reduce the mortality rate among those with what disease? ANS10 hypertension